<?xml version="1.0" encoding="UTF-8"?>
<collection xmlns="http://www.loc.gov/MARC21/slim">
 <record>
  <leader>     caa a22        4500</leader>
  <controlfield tag="001">469104406</controlfield>
  <controlfield tag="003">CHVBK</controlfield>
  <controlfield tag="005">20180323133053.0</controlfield>
  <controlfield tag="007">cr unu---uuuuu</controlfield>
  <controlfield tag="008">170328e19920901xx      s     000 0 eng  </controlfield>
  <datafield tag="024" ind1="7" ind2="0">
   <subfield code="a">10.1007/BF00770608</subfield>
   <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="035" ind1=" " ind2=" ">
   <subfield code="a">(NATIONALLICENCE)springer-10.1007/BF00770608</subfield>
  </datafield>
  <datafield tag="245" ind1="0" ind2="0">
   <subfield code="a">Successes and perspectives in the creation of therapeutic preparations based on ascorbic acid (review)</subfield>
   <subfield code="h">[Elektronische Daten]</subfield>
   <subfield code="c">[É. Parfenov, L. Smirnov]</subfield>
  </datafield>
  <datafield tag="520" ind1="3" ind2=" ">
   <subfield code="a">Conclusions: Thus, increases in therapeutic effects can be achieved by various methods: by increasing ascorbic acid doses, by combing ascorbic acid with synergistic agents, and by using it as a chemoprotector against xenobiotics; the most effective way is by chemical modification. Increasing lipophilicity can widen the spectrum of biological activity in the desired direction, and substitution of the hydroxyl group or the carbon at position 2 prolongs the antioxidant activity of ascorbic acid and its associated pharmacological effects, as does complex formation (when the chemical structure of ascorbic acid is not changed), which increases the antioxidant activity — the most important prerequisite for its biological</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
   <subfield code="a">Plenum Publishing Corporation, 1993</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Parfenov</subfield>
   <subfield code="D">É.</subfield>
   <subfield code="u">All-Union Scientific Center for the Safety of Biologically Active Substances, Kupavna</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Smirnov</subfield>
   <subfield code="D">L.</subfield>
   <subfield code="u">All-Union Scientific Center for the Safety of Biologically Active Substances, Kupavna</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="773" ind1="0" ind2=" ">
   <subfield code="t">Pharmaceutical Chemistry Journal</subfield>
   <subfield code="d">Kluwer Academic Publishers-Plenum Publishers</subfield>
   <subfield code="g">26/9-10(1992-09-01), 657-676</subfield>
   <subfield code="x">0091-150X</subfield>
   <subfield code="q">26:9-10&lt;657</subfield>
   <subfield code="1">1992</subfield>
   <subfield code="2">26</subfield>
   <subfield code="o">11094</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2="0">
   <subfield code="u">https://doi.org/10.1007/BF00770608</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="908" ind1=" " ind2=" ">
   <subfield code="D">1</subfield>
   <subfield code="a">review-article</subfield>
   <subfield code="2">jats</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">856</subfield>
   <subfield code="E">40</subfield>
   <subfield code="u">https://doi.org/10.1007/BF00770608</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Parfenov</subfield>
   <subfield code="D">É.</subfield>
   <subfield code="u">All-Union Scientific Center for the Safety of Biologically Active Substances, Kupavna</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Smirnov</subfield>
   <subfield code="D">L.</subfield>
   <subfield code="u">All-Union Scientific Center for the Safety of Biologically Active Substances, Kupavna</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">773</subfield>
   <subfield code="E">0-</subfield>
   <subfield code="t">Pharmaceutical Chemistry Journal</subfield>
   <subfield code="d">Kluwer Academic Publishers-Plenum Publishers</subfield>
   <subfield code="g">26/9-10(1992-09-01), 657-676</subfield>
   <subfield code="x">0091-150X</subfield>
   <subfield code="q">26:9-10&lt;657</subfield>
   <subfield code="1">1992</subfield>
   <subfield code="2">26</subfield>
   <subfield code="o">11094</subfield>
  </datafield>
  <datafield tag="900" ind1=" " ind2="7">
   <subfield code="a">Metadata rights reserved</subfield>
   <subfield code="b">Springer special CC-BY-NC licence</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="898" ind1=" " ind2=" ">
   <subfield code="a">BK010053</subfield>
   <subfield code="b">XK010053</subfield>
   <subfield code="c">XK010000</subfield>
  </datafield>
  <datafield tag="949" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="F">NATIONALLICENCE</subfield>
   <subfield code="b">NL-springer</subfield>
  </datafield>
 </record>
</collection>
